Literature DB >> 6412268

Relationship between plasma desipramine levels and clinical outcome for RDC major depressive inpatients.

G M Simpson, E H Pi, E Abdelmalek, J L Boyd, R S Carroll, T B Cooper, A Miller.   

Abstract

Depressed patients (N = 31), who met Research Diagnostic Criteria for major affective disorder-depressed, were severely ill and maintained drug-free for a 1-week period on inpatient status. They received a fixed dose (150 mg/day) of desipramine for a 4-week period with drug plasma level determination and clinical ratings performed at fixed time intervals throughout the study. Despite these rigid criteria for entrance and clinical outcome measures, no obvious relationship between plasma desipramine level and clinical outcome was found. The clinical implications of this finding are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6412268     DOI: 10.1007/BF00436161

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Aspects of the clinical chemistry of desmethylimipramine in man.

Authors:  C M YATES; A TODRICK; A C TAIT
Journal:  J Pharm Pharmacol       Date:  1963-07       Impact factor: 3.765

2.  A sensitive GLC method for the determination of imipramine and desmethylimipramine using a nitrogen detector.

Authors:  T B Cooper; D Allen; G M Simpson
Journal:  Psychopharmacol Commun       Date:  1975

3.  Desipramine plasma levels and clinical response in depressed outpatients.

Authors:  R O Friedel; R C Veith; V Bloom; R J Bielski
Journal:  Commun Psychopharmacol       Date:  1979

4.  Imipramine: clinical effects and pharmacokinetic variability.

Authors:  N Reisby; L F Gram; P Bech; A Nagy; G O Petersen; J Ortmann; I Ibsen; S J Dencker; O Jacobsen; O Krautwald; I Sondergaard; J Christiansen
Journal:  Psychopharmacology (Berl)       Date:  1977-11-15       Impact factor: 4.530

5.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

6.  Relationship between plasma antidepressant levels and clinical outcome for inpatients receiving imipramine.

Authors:  G M Simpson; K L White; J L Boyd; T B Cooper; A Halaris; I C Wilson; E J Raman; E Ruther
Journal:  Am J Psychiatry       Date:  1982-03       Impact factor: 18.112

7.  Clinical response, plasma levels and pharmacokinetics of desipramine in depressed in-patients.

Authors:  P D Hrdina; Y D Lapierre
Journal:  Prog Neuropsychopharmacol       Date:  1980

8.  Amitriptyline plasma levels and clinical response in primary depression.

Authors:  D J Kupfer; I Hanin; D G Spiker; T Grau; P Coble
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

9.  A clinical trial comparing sustained release amitryptyline (Saroten Retard) and conventional amitriptyline tablets (Saroten) in endogenously depressed patients with simultaneous determination of serum levels of amitryptyline and nortriptyline.

Authors:  P Liisberg; H Mose; A Amdisen; A Jørgensen; H E Petersen
Journal:  Acta Psychiatr Scand       Date:  1978-05       Impact factor: 6.392

10.  Clinical implications of imipramine plasma levels for depressive illness.

Authors:  A H Glassman; J M Perel; M Shostak; S J Kantor; J L Fleiss
Journal:  Arch Gen Psychiatry       Date:  1977-02
View more
  2 in total

Review 1.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

2.  Potentiation of the action of adenosine on cerebral cortical neurones by the tricyclic antidepressants.

Authors:  J W Phillis
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.